BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 75
- Registration Number
- NCT04382898
- Locations
- 🇬🇧
Cancer Research UK Cambridge Centre, Cambridge, United Kingdom
🇬🇧University of Glasgow, Beatson WoS Cancer Centre, Glasgow, United Kingdom
🇺🇸University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
- Conditions
- Virus DiseasesInfection ViralRNA Virus InfectionsProtection Against COVID-19 and Infections With SARS CoV 2Infections, RespiratoryVaccine Adverse Reaction
- Interventions
- Biological: BNT162c2Biological: BNT162b2Biological: BNT162b1Biological: BNT162a1
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 512
- Registration Number
- NCT04380701
- Locations
- 🇩🇪
Universitäts Klinikum, Heidelberg, Germany
🇩🇪Contract Research Organization, Mannheim, Germany
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: BNT162b1Biological: BNT162b2SAOther: PlaceboBiological: BNT162b2
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 47079
- Registration Number
- NCT04368728
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Lynn Institute of Norman, Norman, Oklahoma, United States
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
- Conditions
- Solid TumorExtensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 54
- Registration Number
- NCT04101357
- Locations
- 🇩🇪
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg, Germany
🇩🇪Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Koeln, Germany
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Lipo-MERIT
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 119
- Registration Number
- NCT02410733
- Locations
- 🇩🇪
Johann Wolfgang Goethe Universität Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany
🇩🇪Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie, Mannheim, Germany
🇩🇪Universitätsmedizin Mainz, Hautklinik und Poliklinik, Mainz, Germany
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Interventions
- Biological: IVAC_W_bre1_uIDBiological: IVAC_W_bre1_uID/IVAC_M_uID
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 42
- Registration Number
- NCT02316457
- Locations
- 🇩🇪
Johannes Gutenberg University, Mainz, RLP, Germany
🇩🇪Dr. Horst Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany
🇩🇪National Center for Tumor Diseases (NCT), Heidelberg, Germany